The inflammatory hypothesis of atherosclerosis postulates that inflammation within the plaque promotes plaque progression and complications. Interleukin-1 (IL-1) is a key pro-inflammatory cytokine responsible for the amplification of the inflammatory response following injury. Animal studies show that IL-1 blockade is effective in limiting atherosclerosis and atherothrombosis and improving outcomes in acute myocardial infarction and ischemic stroke. Preliminary data in patients with acute myocardial infarction, ischemic stroke, and heart failure are promising. A large secondary prevention trial with canakinumab in patients with prior acute myocardial infarction is currently ongoing. Many unanswered questions remain regarding the optimal use of IL-1 blockade and the preferred agent. © 2012 Springer International Publishing AG. All rights reserved.

Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events / Antonio, Abbate; Benjamin W., Van Tassell; BIONDI ZOCCAI, Giuseppe. - In: BIODRUGS. - ISSN 1173-8804. - 26:4(2012), pp. 217-233. [10.2165/11631570-000000000-00000]

Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events

BIONDI ZOCCAI, GIUSEPPE
2012

Abstract

The inflammatory hypothesis of atherosclerosis postulates that inflammation within the plaque promotes plaque progression and complications. Interleukin-1 (IL-1) is a key pro-inflammatory cytokine responsible for the amplification of the inflammatory response following injury. Animal studies show that IL-1 blockade is effective in limiting atherosclerosis and atherothrombosis and improving outcomes in acute myocardial infarction and ischemic stroke. Preliminary data in patients with acute myocardial infarction, ischemic stroke, and heart failure are promising. A large secondary prevention trial with canakinumab in patients with prior acute myocardial infarction is currently ongoing. Many unanswered questions remain regarding the optimal use of IL-1 blockade and the preferred agent. © 2012 Springer International Publishing AG. All rights reserved.
2012
interleukin-1; inflammation; cardiovascular-therapies; atherosclerosis
01 Pubblicazione su rivista::01a Articolo in rivista
Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events / Antonio, Abbate; Benjamin W., Van Tassell; BIONDI ZOCCAI, Giuseppe. - In: BIODRUGS. - ISSN 1173-8804. - 26:4(2012), pp. 217-233. [10.2165/11631570-000000000-00000]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/446666
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 66
  • ???jsp.display-item.citation.isi??? 59
social impact